Coronavirus may lead to medical supply shortages in USA
The US Food and Drug Administration has suspended investigators from China in light of the increasing number of novel coronavirus (COVID-19) cases, which is likely to impact medical supplies in America, says analytics firm GlobalData.
Given this development, the FDA’s suspended service will disrupt the export of food, devices and drugs flowing from China to the USA and consequently the agency has warned Americans that they might face shortages of critical medical products if the outbreak persists, noted GlobalData’s infectious diseases analyst Angad Lotay.
He continued: “China is highly integrated within the global economy and has impressive transportation networks, which means that supply chain disruptions go far beyond regional concerns. With the coronavirus epidemic still on the rise, global supply chains are being disrupted with many industries having to draw up contingency plans.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze